AGARWALEYE500.20

Dr. Agarwal's Health Care Ltd.

· Pharma & Health
₹ CrorePeersAKUMSADVENZYMESALIVUSAARTIPHARMAARTIDRUGSAPLLTDCORONAHCGMcap ₹15,846 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation230.7276.2
+ Impairment Loss / (Reversal)3.00.0
+ Finance Costs79.870.0
+ Interest Income-7.3-11.3
+ Fair Value (Gains) / Losses-2.0-1.3
+ Share-based Payments8.47.4
+ Unrealised FX (Gain) / Loss2.012.6
+ Other Non-cash Items3.5-0.6
+ Other — Cash Effects are Investing / Financing13.3-14.4
+ Other Reconciling Items0.035.6
Changes in Working Capital
+ Inventories-26.5-13.8
+ Trade Receivables — Current-43.6-54.1
+ Other Financial Assets — Current-31.2-17.1
+ Other Financial Assets — Non-current-16.10.0
+ Other Current Assets-8.5-4.5
+ Other Non-current Assets-3.90.8
+ Trade Payables — Current26.60.0
+ Other Financial Liabilities — Current0.028.5
+ Other Financial Liabilities — Non-current-0.70.0
+ Other Current Liabilities5.212.4
+ Provisions — Current4.40.0
Cash from Operating Activities
Profit Before Tax (per I/S)159.9248.6270.2
+ Total Adjustments (incl. Working Capital)237.1326.3
Cash from Operations (pre-tax)396.9575.0
+ Interest Received — Operating0.0-0.9
+ Income Taxes Paid36.655.1
Cash from Operating Activities360.3519.0
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)308.6448.0
+ Acq of Intangible Assets12.312.6
+ Disp of Fixed Assets0.50.9
+ Purchase of Investments (Equity / Debt)0.06.3
+ Acq of Subsidiaries / Businesses (net)515.885.1
+ Interest Received — Investing3.45.3
+ Other Inflows / (Outflows) — Investing82.5237.4
Cash from Investing Activities-750.3-308.5
Cash from Financing Activities
+ Proceeds from Issue of Shares654.911.4
+ Proceeds from Borrowings61.50.0
+ Repayment of Borrowings202.689.6
+ Payment of Lease Liabilities99.0133.2
+ Interest Paid32.27.9
+ Dividends Paid0.81.1
Cash from Financing Activities381.9-220.4
Net Changes in Cash (pre-FX)-8.1-9.9
Net Changes in Cash-8.1-9.9
Closing Cash103.6
Reference Items
EBITDA456.4569.6612.1
EBITDA Margin %26.6727.3827.74
Free Cash Flow (CFO − Capex)39.458.458.4
Free Cash Flow to Equity-39.1
Free Cash Flow per Basic Share1.241.841.84
Price to Free Cash Flow271.29
Cash Flow to Net Income3.273.09
Cash Paid for Taxes36.655.1
Cash Paid for Interest32.27.9
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.